Search Results

Test Catalog

VLTUX - Overview: Volatile Screen, Chain of Custody, Random, Urine

Detecting the presence of acetone, methanol, isopropanol, or ethanol in urine with subsequent quantitation Providing chain of custody for when the results of testing could be used in a court of law. Its purpose is to protect the rights of...

FATF - Overview: Fat, Feces

Diagnosing fat malabsorption due to pancreatic or intestinal disorders Monitoring effectiveness of enzyme supplementation in certain malabsorption disorders This test is not useful for differentiating among pancreatic diseases.

VLTS - Overview: Volatile Screen, Serum

Detection and quantitation of acetone, methanol, isopropanol, and ethanol in serum Quantification of the concentration of ethanol in serum correlates with degree of intoxication Evaluation of toxicity to the measured volatile substances

BARBX - Overview: Barbiturates Confirmation, Chain of Custody, Random, Urine

Detecting drug abuse involving barbiturates such as amobarbital, butalbital, pentobarbital, phenobarbital, and secobarbital Chain of custody is required whenever the results of testing could be used in a court of law. Its purpose is to...

EM - Overview: Electron Microscopy, Varies

Providing information to aid in the diagnosis of medical disorders such as storage diseases, CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy), and primary ciliary dyskinesia

PFAPC - Overview: Fatty Acid Profile, Comprehensive (C8-C26), Plasma

Monitoring patients undergoing diet therapy for mitochondrial or peroxisomal disorders (possibly inducing essential fatty acid deficiency in response to restricted fat intake) using plasma specimens Monitoring treatment of essential fatty...

FAPCP - Overview: Fatty Acid Profile, Comprehensive (C8-C26), Serum

Monitoring patients undergoing diet therapy for mitochondrial or peroxisomal disorders (possibly inducing essential fatty acid deficiency in response to restricted fat intake) using serum specimens Monitoring treatment of essential fatty...

LDALD - Overview: Lysosomal and Peroxisomal Disorders Newborn Screen, Blood Spot

First-tier newborn screen for the lysosomal disorders: Fabry, Gaucher, Krabbe, mucopolysaccharidosis I (MPS I) and II (MPS II), infantile neurovisceral or chronic visceral acid sphingomyelinase deficiency, and Pompe (glycogen storage...

Site Search

Visit Mayo Clinic Laboratories at Medlab Middle East 2023 - Insights

announce our participation in Medlab Middle East 2023, a medical conference and exhibition taking place in Dubai, United Arab Emirates, Feb. 6–9, 2023....

the American Academy of Neurology Annual Meeting 2023 - Insights

Clinic Laboratories is thrilled to participate in the American Academy of Neurology Annual Meeting 2023....

Register today for Classical Hematology 2023 - Insights

Taking place on October 3–4, 2023, in Rochester, Minnesota, the Classical Hematology 2023 conference focuses on addressing the evaluation of frequently encountered blood count abnormalities. The conference...

the American Academy of Neurology Annual Meeting 2023 - Insights

the American Academy of Neurology Annual Meeting, taking place in person in Boston on April 22–27, 2023....

Leveraging the Laboratory 2023 - Insights

Mayo Clinic Laboratories’ Outreach Conference was held Sept. 26-27, 2023, in Chicago. “Leveraging the Laboratory: Dimensions of Outreach” provides innovative views into all aspects of health system laboratory...